Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells
Date
2003Author
Tonetti, D. A.Rubenstein, R.
DeLeon, M.
Zhao, H.
Pappas, S. G.
Bentrem, D. J.
Chen, B.

Jordan, V. C.
Source
Journal of Steroid Biochemistry and Molecular BiologyVolume
87Pages
47-55Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
We previously reported stable transfection of estrogen receptor alpha (ERα) into the ER-negative MDA-MB-231 cells (S30) as a tool to examine the mechanism of action of estrogen and antiestrogens [J. Natl. Cancer Inst. 84 (1992) 580]. To examine the mechanism of ERβ action directly, we have similarly created ERβ stable transfectants in MDA-MB-231 cells. MDA-MB-231 cells were stably transfected with ERβ cDNA and clones were screened by estrogen response element (ERE)-luciferase assay and ERβ mRNA expression was quantified by real-time RT-PCR. Three stable MDA-MB-231/ERβ clones were compared with S30 cells with respect to their growth properties, ability to activate ERE- and activating protein-1 (AP-1) luciferase reporter constructs, and the ability to activate the endogenous ER-regulated transforming growth factor alpha (TGFα) gene. ERβ6 and ERβ27 clones express 300-400-fold and the ERβ41 clone express 1600-fold higher ERβ mRNA levels compared with untransfected MDA-MB-231 cells. Unlike S30 cells, 17β-estradiol (E2) does not inhibit ERβ41 cell growth. ERE-luciferase activity is induced six-fold by E2 whereas neither 4-hydroxytamoxifen (4-OHT) nor ICI 182, 780 activated an AP-1-luciferase reporter. TGFα mRNA is induced in response to E2, but not in response to 4-OHT. MDA-MB-231/ERβ clones exhibit distinct characteristics from S30 cells including growth properties and the ability to induce TGFα gene expression. Furthermore, ERβ, at least in the context of the MDA-MB-231 cellular milieu, does not enhance AP-1 activity in the presence of antiestrogens. In summary, the availability of both ERα and ERβ stable breast cancer cell lines now allows us to compare and contrast the long-term consequences of individual signal transduction pathways. © 2003 Elsevier Ltd. All rights reserved.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms
Liu, J.; Burdette, J. E.; Xu, H.; Gu, C.; Van Breemen, R. B.; Bhat, K. P. L.; Booth, N.; Constantinou, Andreas I.; Pezzuto, J. M.; Fong, H. H. S.; Farnsworth, N. R.; Bolton, J. L. (2001)Eight botanical preparations that are commonly used for the treatment of menopausal symptoms were tested for estrogenic activity. Methanol extracts of red clover (Trifolium pratense L.), chasteberry (Vitex agnus-castus ...
-
Article
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: A translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial
Skarlos, P.; Christodoulou, C.; Kalogeras, K. T.; Eleftheraki, A. G.; Bobos, M.; Batistatou, Anna; Valavanis, C.; Tzaida, O.; Timotheadou, E.; Kronenwett, R.; Wirtz, R. M.; Kostopoulos, I.; Televantou, D.; Koutselini, E.; Papaspirou, I.; Papadimitriou, C.; Pectasides, Dimitrios; Gogas, H.; Aravantinos, Gerasimos; Pavlidis, Nicholas; Arapantoni, P.; Skarlos, Dimosthenis V.; Fountzilas, George (2012)Purpose: It is well recognized that breast cancer is a heterogeneous disease. The purpose of the current study was to classify patients according to the immunohistochemical phenotype of their tumors in an effort to evaluate ...
-
Article
Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance
Pitta, Chara A.; Papageorgis, P.; Charalambous, Christina; Constantinou, Andreas I. (2013)The purpose of this work is to determine the molecular mechanisms underlying tamoxifen resistance. We show here that ER-β is epigenetically silenced in a cell line with acquired tamoxifen resistance (MCF-7/TAM-R) and this ...